Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Nov;11(11):2674-2676.
doi: 10.1158/2159-8290.CD-21-1046.

New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma

Mihaela Aldea  1   2 , Jose Carlos Benitez  1   2 , Nathalie Chaput  3   4 , Benjamin Besse  5   2
Affiliations
Comment

New Immunotherapy Combinations Enter the Battlefield of Malignant Mesothelioma

Mihaela Aldea et al. Cancer Discov. 2021 Nov.

Abstract

Chimeric antigen receptor (CAR) T cells targeting mesothelin plus pembrolizumab, and atezolizumab plus bevacizumab, have recently shown clinical efficacy in phase I trials in malignant pleural and peritoneal mesothelioma. Despite being tested in a highly selected patient population and requiring a complex engineering that can hardly be upscaled, CAR T cells combined with pembrolizumab bring the first proof of efficacy in cold solid tumors with low genomic heterogeneity, while atezolizumab-bevacizumab offers an easy-to-use combination of antiangiogenics and immunotherapy in an orphan disease.See related article by Raghav et al., p. 2738.See related article by Adusumilli et al., p. 2748.

PubMed Disclaimer

Comment on

References

    1. Kindler HL, Ismaila N, Armato SG III, Bueno R, Hesdorffer M, Jahan T, et al. Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1343–73.
    1. Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375–86.
    1. Broeckx G, Pauwels P. Malignant peritoneal mesothelioma: a review. Transl Lung Cancer Res. 2018;7:537–42.
    1. Takeda M, Kasai T, Enomoto Y, Takano M, Morita K, Nakai T, et al. Comparison of genomic abnormality in malignant mesothelioma by the site of origin. J Clin Pathol. 2014;67:1038–43.
    1. Raghav K, Liu S, Overman MJ, Willett AF, Knafl M, Fu S-C, et al. Efficacy, safety, and biomarker analysis of combined PD-L1 (atezolizumab) and VEGF (bevacizumab) blockade in advanced malignant peritoneal mesothelioma. Cancer Discov. 2021;11:2738–47.

LinkOut - more resources